135 related articles for article (PubMed ID: 7774832)
1. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
[TBL] [Abstract][Full Text] [Related]
2. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
3. Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.
Venesmaa P; Ylikorkala O
Br J Cancer; 1991 Jan; 63(1):84-6. PubMed ID: 1899195
[TBL] [Abstract][Full Text] [Related]
4. Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA).
Stratton JA; Rettenmaier MA; Kucera PR; Berman ML; DiSaia PJ
Gynecol Oncol; 1988 Jul; 30(3):416-21. PubMed ID: 3391423
[TBL] [Abstract][Full Text] [Related]
5. Subrenal capsule assay as a test to predict the effectiveness of chemotherapy in choriocarcinoma.
Ogino M; Sakamoto T; Yamamoto T; Mori H; Okinaga S; Arai K
Gynecol Oncol; 1990 Jul; 38(1):32-6. PubMed ID: 2354824
[TBL] [Abstract][Full Text] [Related]
6. [Responsiveness of gynecological malignancies to oral antitumor agents in subrenal capsule assay and individualization of oral adjuvant chemotherapy].
Sekiguchi I; Suzuki M; Aida I; Tamada T; Nishida M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):437-42. PubMed ID: 2115558
[TBL] [Abstract][Full Text] [Related]
7. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
8. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
9. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
10. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
Hernádi Z; Juhász B; Póka R; Lampé LG
Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
[TBL] [Abstract][Full Text] [Related]
11. [Clinical application of subrenal capsule assay in ovarian cancer].
Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural effects of alpha and gamma interferons and cytostatics on ovarian cancer cells in the subrenal capsule assay (SRCA).
Söderström KO; Mäenpää J; Cantell K; Kangas L; Grönroos M
Ann Chir Gynaecol Suppl; 1985; 199():38-43. PubMed ID: 3933399
[TBL] [Abstract][Full Text] [Related]
13. Predictive testing of vulvar and cervical cancers to chemotherapy by the subrenal capsule assay.
Mäenpää J; Kangas L; Grönroos M
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1141-6. PubMed ID: 4076281
[TBL] [Abstract][Full Text] [Related]
14. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer.
Suonio E; Lipponen P; Mäenpää J; Syrjänen K; Kangas L; Tuomisto L
Cancer Chemother Pharmacol; 1997; 41(1):15-21. PubMed ID: 9443609
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer.
Mäenpää J; Sipilä P; Kangas L; Karnani P; Grönroos M
Gynecol Oncol; 1992 Sep; 46(3):292-7. PubMed ID: 1388131
[TBL] [Abstract][Full Text] [Related]
17. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
[TBL] [Abstract][Full Text] [Related]
18. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
19. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
20. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]